VAN-TELMISARTAN-HCTZ TABLET

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

TELMISARTAN; HYDROCHLOROTHIAZIDE

Disponible des:

VANC PHARMACEUTICALS INC

Codi ATC:

C09DA07

Designació comuna internacional (DCI):

TELMISARTAN AND DIURETICS

Dosis:

80MG; 25MG

formulario farmacéutico:

TABLET

Composición:

TELMISARTAN 80MG; HYDROCHLOROTHIAZIDE 25MG

Vía de administración:

ORAL

Unidades en paquete:

28/30/100

tipo de receta:

Prescription

Área terapéutica:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Resumen del producto:

Active ingredient group (AIG) number: 0244783002; AHFS:

Estat d'Autorització:

CANCELLED PRE MARKET

Data d'autorització:

2019-07-31

Fitxa tècnica

_VAN-Telmisartan-HCTZ Product Monograph _
_ _
_ Page 1 of 53_
PRODUCT MONOGRAPH
Pr
VAN-TELMISARTAN-HCTZ
Telmisartan / Hydrochlorothiazide Tablets
80 mg/12.5 mg and 80 mg/25 mg
Manufacturer’s Standard
Angiotensin II AT
1
Receptor Blocker/Diuretic
MANUFACTURER AND DISTRIBUTOR:
Vanc Pharmaceuticals Inc.
Building 152, 11782 River Road
Richmond, BC V6X 1Z7
www.vancpharm.com
Date of Preparation:
November 7, 2014
Submission Control No: 179134
_VAN-Telmisartan-HCTZ Product Monograph _
_ _
_ Page 2 of 53_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................. 3
SUMMARY PRODUCT INFORMATION
.................................................................... 3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND PRECAUTIONS
...............................................................................
4
ADVERSE REACTIONS
...............................................................................................
11
DRUG INTERACTIONS
................................................................................................
21
DOSAGE AND ADMINISTRATION
...........................................................................
25
OVERDOSAGE
...............................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
........................................................ 28
STORAGE AND STABILITY
.......................................................................................
33
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................ 34
PART II: SCIENTIFIC INFORMATION
.......................................................................
35
PHARMACEUTICAL INFORMATION
.....................................................................
35
CLINICAL TRIALS
.......................